4D Molecular Therapeutics FDMT
NASDAQ FDMT
$12.78 +0.16 (+1.31%)
As of: Oct 22, 2026 · 10:16 AM EDT

4D Molecular Therapeutics (FDMT) Receivables - Other (2021)

Updated

4D Molecular Therapeutics (FDMT) reported Receivables - Other of $561,000 for Q1 2021.

Analysis

4D Molecular Therapeutics (FDMT) Receivables - Other (2021) Analysis & Trends

At the end of FY2020, 4D Molecular Therapeutics posted Receivables - Other of $169,000, up 13.4% from FY2019.

  • By year, Receivables - Other came in at $149,000 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,164.71 Bn 1,133.30 Bn 19.71 Bn
2 Johnson & Johnson 633.37 Bn 551.90 Bn 17.26 Bn
3 AbbVie 503.99 Bn 477.10 Bn 12.70 Bn
4 Merck 378.19 Bn 332.57 Bn 12.21 Bn
5 Novartis Ag 303.15 Bn 267.14 Bn 11.24 Bn
6 Astrazeneca 266.17 Bn 239.85 Bn 12.86 Bn
7 Amgen 241.38 Bn 196.78 Bn 7.24 Bn
8 Gilead Sciences 194.07 Bn 168.27 Bn 6.22 Bn
9 Pfizer 172.31 Bn 118.96 Bn 10.94 Bn
10 4D Molecular Therapeutics 898.43 Mn -561.52 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 561,000.00
API Access

4D Molecular Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=FDMT&period=max&api_key=YOUR_API_KEY